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ABSTRACT
Targeted agents have revolutionized the 
management of metastatic renal cell carcinoma 
(RCC). Axitinib, an inhibitor of vascular 
endothelial growth factor receptor (VEGFR), 
has been an important addition to currently 
available therapies for advanced RCC. Its 
ability to inhibit VEGFRs at nanomolar 
concentrations distinguishes it as a potent 
tyrosine kinase inhibitor, with increased 
selectivity for VEGFR-1, 2, and 3 at clinically 
applicable concentrations. The phase 3 AXIS 
trial has established its superiority in prolonging 
progression-free survival (PFS) in previously 
treated RCC patients (median PFS 6.7 months 
for axitinib vs. 4.7 months for sorafenib).
Common toxicities of axitinib include 
hypertension, diarrhea, nausea, hand-foot 
syndrome, fatigue, and hypothyroidism. 
Axitinib-induced diastolic blood pressure 
elevation may be associated with improved 
clinical outcome, likely reflecting the “on-target” 
effect of axitinib. Dose escalation to achieve 
therapeutic plasma drug levels is of considerable 
clinical interest. Although axitinib has 
established efficacy in patients treated with one 
previous agent, its use in the frontline setting is 
currently the subject of ongoing research. 
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INTRODUCTION
The treatment of metastatic renal cell 
carcinoma (mRCC) has historically included 
immunotherapy, although targeted agents have 
revolutionized treatment strategies over the last 
several years. The management of mRCC has 
evolved rapidly since 2005, when sorafenib, 
a tyrosine kinase inhibitor (TKI) of vascular 
endothelial growth factor receptor (VEGFR),
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was approved for advanced RCC following 
a phase 3 study in patients who had failed to 
respond to prior systemic therapy [1, 2]. Since 
then, newer VEGFR inhibitors, including 
sunitinib and pazopanib, have been approved 
in advanced renal cell carcinoma (RCC) in 
2006 and 2009, respectively [3–5]. Additionally, 
bevacizumab, a monoclonal antibody to 
circulating vascular endothelial growth factor 
(VEGF), was approved in 2009 for mRCC 
patients in combination with interferon 
alpha [6, 7]. Newer, more biochemically potent 
VEGF-TKIs, such as axitinib, have expanded the 
armamentarium of available drugs with targeted 
action and established efficacy in mRCC. 
Angiogenesis and neovascularization are key 
to proliferation and dissemination of neoplastic 
cells in many solid tumors. In sporadic 
RCC, mutations in the Von Hippel-Lindau 
(VHL) gene lead to decreased degradation of 
hypoxia-inducing factor (HIF), and subsequent 
upregulation of VEGF expression [8]. VEGF, 
a mitogen of endothelial cells, promotes 
angiogenesis and vascular permeability. 
Additionally, it also induces expression of 
plasminogen activators and metalloproteinases; 
thereby, promoting a prodegradative 
environment, facilitating cellular migration 
and invasion [9]. Downstream signaling upon 
activation of VEGFRs has also been associated 
with inhibition of apoptosis and decreased 
production of nitric oxide [10]. Thus, the 
VHL-HIF pathway is pivotal to the pathobiology 
of RCC, and has been crucial in the development 
of targeted agents that include VEGFR inhibitors 
as well as antibodies to circulating VEGF. 
Furthermore, mammalian target of rapamycin 
(mTOR) molecules that are downstream 
of phosphoinositide 3-kinase and protein 
kinase B pathways have also demonstrated an 
increased concentration of HIF-alpha; thus, 
playing a significant role in angiogenesis [11].
This has expanded available molecular targets 
and led to the development of mTOR inhibitors, 
temsirolimus and everolimus, which have 
demonstrated efficacy in mRCC [12, 13]. 
Since its Food and Drug Administration 
(FDA) approval in January 2012, the receptor 
selectivity, potency, high objective response rate 
(ORR), and tolerability of axitinib have generated 
considerable interest. The clinical evidence 
supporting the current role of axitinib in the 
management of mRCC is reviewed in this article, 
with a special emphasis on its place in current 
treatment regimens. In addition, management 
of drug toxicities and ongoing investigational 
trials centered on axitinib are detailed.
METHODS
A PubMed search was conducted using the 
key terms “axitinib” and “renal cell cancer.” 
Additionally, proceedings from major congresses 
in North America and Europe over the last 
5 years were reviewed for abstracts related to 
axitinib in RCC.
MECHANISM OF ACTION
Axitinib is a second-generation, indazole-
derived molecule that inhibits VEGFR-1, 2, 
and 3 at therapeutic plasma concentrations; 
thereby, blocking VEGF-mediated angiogenesis, 
cellular adhesion, migration, and eventually 
resulting in cellular apoptosis. Axitinib binds 
selectively to the adenosine triphosphate 
(ATP)-binding intracellular domain of VEGFR-1, 
2, and 3 at nanomolar concentrations, 
stabilizing an inactive confirmation of these 
kinases and, thus, inhibiting downstream signal 
transduction [14, 15]. In fact, the half maximal 
inhibitory concentration (IC50) of axitinib for 
VEGFR-1, 2, and 3 inhibition is 0.1, 0.2, and 
0.1–0.3 nM, respectively, distinguishing it as the 
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most potent VEGFR-1 inhibitor for the treatment 
of mRCC [16]. Despite platelet-derived growth 
factor receptor and C-Kit inhibitory effects 
observed in vitro, axitinib’s potency against 
non-VEGF receptors is about eight-times weaker 
and, at clinically achieved plasma levels, VEGF 
inhibition alone is believed to be responsible for 
the observed clinical benefits [10]. This selectivity 
is likely responsible for the potent “on-target” 
effect and toxicity profile of this agent. 
CLINICAL DATA
In the first phase 1 study of axitinib, 36 patients 
with advanced solid malignancies were treated 
with axitinib with total daily dose varying from 
10–60 mg [17]. This trial helped define the 
maximal tolerated dose of axitinib as 5 mg orally 
twice a day (b.i.d.). Important dose-limiting 
toxicities included hypertension, diarrhea, 
and stomatitis. The incidence and severity of 
hypertension were proportional to drug dosage. 
Linear pharmacokinetics were observed in the 
dose range evaluated in this trial. Subsequent 
phase 1 studies conducted among Japanese 
and Chinese patients have confirmed similar 
pharmacokinetics and the adverse-effect profile 
of axitinib in non-Caucasian subjects [18, 19]. 
Another phase 1 study of axitinib in 12 Japanese 
patients confirmed the tolerability and efficacy 
of this dose, and demonstrated a significant 
correlation between axitinib exposure and 
decline in soluble VEGFR-2 levels [20]. 
Three independent phase 2 tr ials 
subsequently evaluated the role of axitinib 
in mRCC patients refractory to prior therapy 
(Table 1) [21–23]. In the initial single-arm phase 
2 study published in 2007, 52 mRCC patients 
with a performance status of Eastern Cooperative 
Group 0–1, who had previously failed to 
respond to cytokine therapy, were assigned to 
receive axitinib starting at 5 mg b.i.d. [21]. The 
primary endpoint was ORR. The median age of 
the cohort was 59 years, and patients underwent 
close monitoring for hypertension, proteinuria, 
and other adverse effects. The ORR was 44.2% 
(95% confidence intervals [CI] 30.5–58.7%) and 
after a median follow-up period of 31 months, 
median overall survival (OS) was 29.9 months 
(95% CI 20.3, to not estimable; range 2.4–35.8 
months). Another secondary endpoint was time 
to progression, which was 15.7 months. The 
5-year OS rate of this cytokine-refractory mRCC 
population was 20.6%, as assessed during long-
term follow-up [24]. Also, this longer follow-up 
did not reveal any new toxicity in the patient 
cohort [24]. Narrower distribution of peak drug 
concentration on day 1 of cycle 1, higher ORR, 
and better baseline performance status were 
characteristics significantly associated with 
5-year survival. 
Subsequently, a second phase 2 study of 
62 patients was conducted to evaluate response 
to axitinib in patients who had received prior 
VEGF therapy with sorafenib [22]. In this 
single-arm study, dose escalation was permitted 
if standard 5 mg b.i.d. dosing was tolerated. 
Additionally, the protocol allowed for dose 
reduction or interruption for grade 3–4 (severe, 
disabling, or life-threatening) nonhematologic 
toxicities (per National Cancer Institute 
Common Terminology Criteria for Adverse 
Table 1  Summary of phase 2 trials of axitinib
Patients ORR TTP/PFS OS
 (%) (months)  (months)
Cytokine refractory [21] 44.2 15.7 29.9
Sorafenib refractory [22] 22.6 7.4 13.6
Cytokine refractory [23] 50.0 11.0 NR
Table 1 summarizes data from phase 2 axitinib trials, 
references listed in parenthesis 
NR not reported, ORR objective response rate, OS overall 
survival, PFS progression-free survival, TTP time to 
progression
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Events [NCI-CTCAE], version 3.0). A total of 
53.2% of patients were able to tolerate dose 
increases to 7 or 10 mg b.i.d, while 17.7% of 
patients required dose reductions to ≤5 mg b.i.d. 
The primary endpoint of ORR was 22.6% (95% 
CI 12.9–35.0%). With a median follow-up of 
22.7 months, median progression-free survival 
(PFS) was 7.4 months (95% CI 6.7–11.0 months), 
and median OS was 13.6 months (95% CI 8.4–
18.8 months). Interestingly, 80% of the evaluable 
patients had some degree of tumor shrinkage. 
A phase 2 study of axitinib in Japanese 
patients who were cytokine refractory has also 
yielded similar results, with an ORR of 50.0%, 
and median PFS of 11.0 months, which confirms 
the previously observed efficacy and tolerability 
in non-Caucasian populations [23]. 
Phase 3 AXIS Study
The AXIS trial was a pivotal, phase 3, randomized 
controlled study of 723 patients, which 
compared two targeted agents in mRCC wherein 
patients were randomized to receive either 
axitinib 5 mg b.i.d. or sorafenib 400 mg b.i.d. 
(standard of care) [25]. The primary endpoint of 
median PFS was 6.7 months for axitinib versus 
4.7 months for sorafenib (hazard ratio [HR] for 
disease progression or death of 0.665 [95% CI 
0.544–0.812], P < 0.0001; Fig. 1a) [25]. Median 
PFS for patients who had previously received 
cytokine therapy was 12.1 months for axitinib 
and 6.5 months for sorafenib (HR = 0.464; 
95% CI 0.318–0.676; P < 0.0001; Fig. 1b). Among 
patients previously treated with sunitinib, 
median PFS was 4.8 months for axitinib and 
3.4 months for sorafenib (HR = 0.741; 95% CI 
0.573–0.958; P = 0.0107; Fig. 1c). Secondary 
endpoints included ORR, OS, and safety and 
tolerability. ORR was 19.4% (95% Cl 15.4–23.9%) 
versus 9.4% (95% CI 6.6–12.9%) with axitinib 
and sorafenib, respectively. 
The prolonged PFS with both axitinib and 
sorafenib in sunitinib-refractory cases, although 
modest, provides evidence favoring lack of cross-
resistance between different VEGFR inhibitors. 
These data support the use of sequential VEGFR 
inhibitors, although optimal sequencing to 
maximize PFS in mRCC is currently the subject 
of ongoing research [26–29]. 
Secondary analysis of the AXIS trial has 
suggested that of the nearly 54% of patients 
(in both sorafenib and axitinib arms) who had 
received prior sunitinib, those who had received 
≥9 months of front-line VEGFR inhibitor tended 
to have greater PFS (6.3 months vs. 4.5 months 
for axitinib; 4.6 vs. 2.9 months for sorafenib), 
although these data are to be regarded as 
hypothesis-generating given the retrospective 
nature and small subsets with overlapping 
CIs [30]. Upcoming trials of sequential therapy 
may reflect further on this observation. 
In the AXIS trial, patient-reported outcomes 
were assessed by the Functional Assessment of 
Cancer Therapy Kidney Symptom Index (FKSI) 
questionnaire, as well as FKSI-Disease Related 
Symptoms (FKSI-DRS) subscale, at the onset of 
therapy and then monthly until 28 days after 
the last drug dose [25]. An analysis of time to 
deterioration demonstrated 17% reduction in 
FKSI (P = 0.014) and 16% reduction in FKSI-
DRS (P = 0.0203) with axitinib compared with 
sorafenib. These data suggest that the benefit 
in PFS gained with axitinib is accompanied by 
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3.4 (95% CI 2.8–4.7)
P = 0.0107
Stratied HR = 0.741
(95% CI 0.573–0.958)
Number at risk
 Axitinib 184 132 97 60 34 24 11 10 6 1 0
 Sorafenib 185 104 67 37 20 13 5 3 1 0 0 
Sorafenib
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Fig. 1 Kaplan-Meier-estimated median PFS in all patients (a), patients previously treated with cytokine-based regimen 
(b), and patients previously treated with sunitinib-based regimen (c), who received axitinib or sorafenib as second-line 
therapy for metastatic renal cell cancer. Reproduced with permission from Rini BI, Escudier B, Tomczak P, et al. Comparative 
effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 
2011;378:1931–9. PFS progression-free survival, HR hazard ratio
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manufacturer’s guidelines, it may be taken with 
or without meals [32]. B.i.d. dosing achieves 
1.4-fold greater accumulation compared with 
once-a-day dosing. With a plasma half-life of 
2.5–6.1 hours, steady state is achieved within 
2–3 days. The drug is primarily metabolized 
by cytochrome P450 (CYP) 3A4/5, and to 
a lesser extent by CYP1A2, CYP2C19, and 
uridine diphosphate glucuronosyltransferase 1 
polypeptide A1 (UGT1A1) [33]. Axitinib is an 
inhibitor of the efflux transporter P-glycoprotein 
(P-gp) in vitro, but is not expected to inhibit P-gp 
at therapeutic plasma concentrations. Axitinib 
is eliminated by hepatobiliary excretion and 
phase 1 studies have suggested <1% excretion 
of the drug in urine [17]. Dose modifications are 
not recommended for patients with mild hepatic 
impairment (Child-Pugh A) [34]. While axitinib 
has not been studied in patients with severe 
hepatic failure (Child-Pugh C), the starting 
dose should be reduced by 50% in patients with 
moderate hepatic failure (Child-Pugh B). The 
incidence of grade 3–4 transaminitis (defined 
as aspartate transaminase [AST], alanine 
aminotransferase [ALT] >5–10-times the upper 
limit of normal) is <1%; however, baseline 
and periodic monitoring of AST, ALT, and 
bilirubin are recommended through the course 
of treatment for all patients. No starting dose 
adjustments have been recommended in pre-
existing mild-to-severe renal impairment, but 
caution is advised in end-stage renal disease 
(creatinine clearance <15 mL/min) [32].
Coadministration of axitinib with strong 
CYP3A4/5 inhibitors (e.g.,  grapefruit, 
ketoconazole, itraconazole, clarithromycin, 
atazanavir) may increase axitinib plasma 
concentrations.  On the other hand, 
coadministration with strong CYP3A4/5 inducers 
(e.g., rifampin, dexamethasone, phenytoin, 
carbamazepine, rifabutin, and St. John’s Wort) 
may decrease plasma concentrations [32]. 
Pharmacodynamic Variability
Investigators recently analyzed single 
nucleotide polymorphisms (SNPs) in VEGF and 
related receptors, and their correlation with 
hypertension and PFS in the phase 3 axitinib 
AXIS study [35]. Preliminary data suggest that 
three VEGF-A SNPs revealed potential association 
between VEGF genotype and PFS. Although 
these data are preliminary, it is noteworthy 
that these polymorphisms were not associated 
with axitinib-related hypertension or diastolic 
hypertension [35]. Additionally, a meta-analysis 
of pooled data from 11 axitinib studies has not 
revealed a significant association linking gene 
polymorphism for enzymes CYP3A4/5, CYP1A2, 
CYP2C19, UGT1A1, and P-gp to variations 
in axitinib pharmacokinetics [36]. Additional 
investigation into pharmacogenomics as they 
relate to axitinib efficacy and toxicity is needed.
DOSE ESCALATION
In the AXIS trial, dose escalation of axitinib 
was permitted based on physician discretion in 
patients without hypertension (defined as blood 
pressure ≥150/90 mmHg), absence of toxicities 
more than grade 2 (by Common Terminology 
Criteria for Adverse Events [CTCAE] version 3.0), 
and absence of the use of antihypertensive 
agents. In patients satisfying these criteria, dose 
escalation was allowed from 5 to 7 mg b.i.d. 
after 2 weeks. Additionally, dose escalation 
was permitted in another 2 weeks to 10 mg 
b.i.d. in patients who continued to satisfy the 
above criteria, with additional provision for 
dose reduction in cases of adverse toxicities and 
physician discretion used throughout [25].
Results of a secondary analysis did not 
reveal a significant difference in median PFS 
among patients who received daily doses 
of axitinib ≤10 mg compared with patients 
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receiving higher doses of axitinib, with both 
groups having better PFS than the sorafenib 
arm [30]. This result is to be expected on the 
basis of axitinib pharmacokinetics. That is, 
patients who tolerated the 5 mg b.i.d. standard 
starting dose may have subtherapeutic axitinib 
drug levels. Dose escalation to 7 or 10 mg b.i.d. 
elevates axitinib drug levels in those patients to 
above threshold, comparable to patients who 
do experience hypertension or other toxicity 
at 5 mg b.i.d. Thus, dose titration with axitinib 
normalizes blood levels in a subset of patients, 
allowing them to achieve therapeutic axitinib 
levels and, thus, an antitumor effect. Given 
interpatient variability in the ability to achieve 
therapeutic plasma drug levels, dose escalation 
of axitinib is critical for optimal administration, 
as is true for many, if not all oral agents.
Enrollment for a randomized phase 2 study 
to evaluate efficacy of front-line axitinib with 
dose titration in 200 treatment-naive patients 
has been completed [37]. In this study, after 
4 weeks of standard dosing (5 mg b.i.d.), eligible 
patients were randomized to a dose titration 
arm (standard dose plus escalating doses of 
axitinib, arm A) versus standard dose and 
escalating doses of placebo (arm B). Eligibility 
for dose titration was based on absence of 
hypertension (>150/90 mmHg), grade 3 or 4 
toxicities, prior dose reduction, and use of more 
than two antihypertensive agents. Patients not 
meeting randomization criteria for dose titration 
continued on standard dosing in a third arm 
(arm C). Preliminary analysis performed in 
a subpopulation that had pharmacokinetic 
assessments on day 15 of cycle 1 indicated 
that patients with drug exposure above the 
therapeutic threshold (area under the plasma 
concentration time curve from 0–12 h [AUC0–12] 
≥150 ng/mL) on day 15 of cycle 1 had a 
longer median PFS and higher ORR than those 
with subtherapeutic exposure (median PFS: 
13.9 months vs. 8.3 months; ORR: 59% vs. 48%). 
In a blinded pooled analysis of the entire enrolled 
population, ORR in arm C was higher (56.0%; 
95% CI 45.2–66.4%) compared with arms A+B 
(40.2%; 95% CI 31.0–49.9). These data suggest 
that response rates and PFS more likely depend 
on achievement of therapeutic concentration of 
axitinib, rather than specific drug dosage. This 
lends support to consideration of dose escalation 
to improve treatment response, by optimization 
of plasma drug levels. The unblinding of this 
study and comparison of patients eligible for 
dose titration who underwent dose escalation 
versus patients who did not, will provide more 
definitive insight into the clinical utility of dose 
escalation.
Dose Titration
Currently, the recommended oral starting dose 
of axitinib is 5 mg b.i.d. Periodic monitoring of 
blood pressure is recommended. In patients who 
do not develop dose-limiting toxicity (grade 3 
or 4), are normotensive, and are not receiving 
antihypertensive agents, uptitration to 7 mg 
b.i.d. 2 weeks after initiation is suggested. Using 
the same principle, the dose can be increased 
to a maximum of 10 mg b.i.d. In patients who 
require dose reduction because of adverse effects, 
a decrease to 3 mg b.i.d. is recommended. 
Further dose reduction to 2 mg b.i.d. may be 
necessary in some cases. 
TOXICITIES AND THEIR 
MANAGEMENT
Based on results of the AXIS trial, common 
adverse effects of axitinib that have been 
observed in over 30% of patients (all grade 
toxicities) include diarrhea, hypertension, 
fatigue, nausea, lack of appetite (anorexia), and 
dysphonia [25]. Among laboratory abnormalities, 
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anemia, hypothyroidism, lymphopenia, 
and hypocalcemia were commonly seen. 
Less common side effects included bleeding, 
thromboembolism, and proteinuria. Table 2 [25] 
summarizes the various grades of toxicities 
observed in the phase 3 study. The decreased 
incidence of myelosuppression, hand-foot 
syndrome (palmar-plantar erythrodysesthesia), 
Table 2  Common treatment-emergent all-causality adverse events in the phase 3 AXIS trial
 Treatment-emergent events Axitinib  (n = 359) Sorafenib (n = 355)
  All grades ≥Grade 3 All grades ≥Grade 3
Adverse events    
 Diarrhea 197 (55) 38 (11) 189 (53) 26 (7)
 Hypertension 145 (40) 56 (16) 103 (29) 39 (11)
 Fatigue 140 (39) 41 (11) 112 (32) 18 (5)
 Decreased appetite 123 (34) 18 (5) 101 (29) 13 (4)
 Nausea 116 (32) 9 (3) 77 (22) 4 (1)
 Dysphonia 111 (31) 0 48 (14) 0
 Palmar-plantar erythrodysesthesia 98 (27) 18 (5) 181 (51) 57 (16)
 Weight decreased 89 (25) 8 (2) 74 (21) 5 (1)
 Vomiting 85 (24) 12 (3) 61 (17) 3 (1)
 Asthenia 74 (21) 19 (5) 50 (14) 9 (3)
 Constipation 73 (20) 4 (1) 72 (20) 3 (1)
 Hypothyroidism 69 (19) 1 (<1) 29 (8) 0
 Cough 55 (15) 3 (1) 59 (17) 2 (1)
 Mucosal inflammation 55 (15) 5 (1) 44 (12) 2 (1)
 Arthralgia 54 (15) 5 (1) 39 (11) 5 (1)
 Stomatitis 54 (15) 5 (1) 44 (12) 1 (<1)
 Rash 45 (13) 1 (<1) 112 (32) 14 (4)
 Alopecia 14 (4) 0 115 (32) 0
Laboratory abnormalitiesa
 Anemia 113/320 (35) 1/320 (<1) 165/316 (52) 12/316 (4)
 Hemoglobin elevation 31/320 (10) NA 3/316 (1) NA
 Neutropenia 19/316 (6) 2/316 (1) 26/308 (8) 2/308 (1)
 Thrombocytopenia 48/312 (15) 1/312 (<1) 44/310 (14) 0
 Lymphopenia 106/317 (33) 10/317 (3) 111/309 (36) 11/309 (4)
 Creatinine elevation 185/336 (55) 0 131/318 (41) 1/318 (<1)
 Hypophosphatemia 43/336 (13) 6/336 (2) 158/318 (50) 51/318 (16)
 Hypercalcemia 19/336 (6) 0 5/319 (2) 0
 Hypocalcemia 132/336 (39) 4/336 (1) 188/319 (59) 5/319 (2)
 Lipase elevation 91/338 (27) 16/338 (5) 148/319 (46) 47/319 (15)
Reproduced with permission from Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in 
advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378:1931–9
Data are n (%)
NA not available
a Denominator for each laboratory abnormality differed depending on the availability of baseline and at least one on-study 
test result
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and cutaneous toxicities with axitinib compared 
with other VEGFR inhibitors is a potential 
advantage of axitinib. 
The most important component of side-
effect management is patient education prior to 
treatment initiation. The clinician’s knowledge 
of common side effects provides the basis for 
focused education. Patient education should 
include necessary information regarding the 
treatment plan, dosing, and potential drug–drug 
interactions (Table 3) [38].
Hypertension should be controlled prior to 
the initiation of therapy. Home blood pressure 
assessments should be individualized based 
on the patient’s medical history, concomitant 
medications, and drug therapy. Patients with a 
history of hypertension, cardiac co-morbidities, 
renal dysfunction, or diabetes should be 
closely monitored for treatment-induced 
hypertension [39]. Early awareness of changes 
in home blood pressure assessments allows the 
clinician to begin or adjust antihypertensive 
medications, improve control of hypertension, 
and minimize the patient’s risk of developing 
hypertension-related toxicity. 
Management of  axit inib-associated 
gastrointestinal side effects includes dietary 
and medication interventions. Information 
about dietary management of diarrhea should 
be given to the patient prior to the initiation 
of therapy, including consumption of bananas 
and rice, and the avoidance of spicy foods. 
Pharmacologic interventions include loperamide, 
diphenoxylate hydrochloride/atropine sulfate, 
tincture of opium, probiotics, and psyllium fiber 
supplements [40]. Avoiding caffeinated beverages 
and increasing fluid intake can decrease the 
potential for diarrhea, dehydration, and 
renal dysfunction. Frequent meals, increasing 
calorie intake, nutritional supplements, and 
consultation with a nutritionist can minimize 
the negative impact of anorexia.
Hand-foot syndrome is a class effect of 
VEGF-TKIs, and requires ongoing assessment 
and management to control the extent and 
severity of this adverse event. Assessment of skin 
condition and noting the presence of calluses or 
structural abnormalities that increase pressure on 
bony prominences should be done at baseline, 
at each clinic visit, and discussed during phone 
assessments thereafter. Instructions regarding 
proactive skin care and supportive footwear 
should be provided at baseline, with ongoing 
evaluation and adjustment of interventions 
throughout treatment. The “3C” approach to 
management of hand-foot syndrome includes 
controlling calluses, comforting with cushions, 
and covering with creams, and provides an 
Table 3  Instructions to include in patient information 
packet for axitinib
•	 Treatment information regarding axitinib drug 
formulation and dosing.
•	 Information regarding possible food and drug 
interactions, and other precautions to consider with 
axitinib therapy.
•	 Possible side effects, prevention, and early management 
strategies. This should include a discussion regarding 
which side effects may be prevented or less severe with 
prophylactic management (i.e., initiation of oral and 
skin care regimens prior to initiation of treatment).
•	 Contact information for their nurse, oncologist, and 
other healthcare team members, including who (and 
how) to contact when the office is closed. Emphasize 
the importance of early communication with the 
nurse/oncologist as side effects develop.
•	 Specific instructions regarding home monitoring of 
blood pressure.
•	 Daily log to record the day, dose, and time of drug 
administration, along with space to document side 
effects and blood pressure measurements.
Reproduced with permission from Wood LS, Gornell S, Rini 
BI. Maximizing clinical outcomes with axitinib therapy in 
advanced renal cell carcinoma through proactive side-effect 
management. Comm Oncol. 2012;9:46–55
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easy-to-remember method for patient education 
and intervention strategies [41, 42]. 
Treatment  modif icat ion including 
interruption and dose modification may be 
required in spite of effective patient education, 
proactive strategies, and frequent and ongoing 
communication to adjust interventions for 
drug-related side effects. Interventions directed 
at fatigue include energy conservation, activity 
enhancement, psychosocial and nutritional 
interventions, and psychostimulants after ruling 
out other causes of fatigue [43]. Hypothyroidism 
is also associated with the increased incidence 
of fatigue, emphasizing the importance of 
obtaining baseline and ongoing thyroid 
function testing [38, 43]. Hypothyroidism with 
VEGFR inhibitors may result from inhibition of 
angiogenesis around the thyroid gland. Thus, 
periodic monitoring of thyroid function is 
recommended. 
Hypertension as a Biomarker
Hypertension is a significant adverse effect of 
axitinib, with reported incidence (all grades 
included) of approximately 40–50% [25]. 
Hypertension as a class effect of VEGF-TKIs 
may be secondary to reduced production of 
the vasodilator, nitric oxide, which is a VEGFR-
mediated phenomenon [44]. Thus, hypertension 
may be a surrogate marker of “on-target” activity 
of axitinib. This was revealed in a retrospective 
study of five, phase 2 trials of single-agent 
axitinib [45], wherein diastolic hypertension 
(defined as diastolic blood pressure ≥90 mmHg) 
was associated with a lower relative risk of 
disease progression (HR = 0.76; 95% CI 0.54–
1.06; P = 0.107]. Furthermore, in an 8-week 
landmark analysis, diastolic hypertension was 
associated with improved OS (Fig. 2) [45]. In 
this 8-week analysis, median PFS for the two 
mRCC studies was noted to be significantly 
higher in patients with diastolic hypertension: 
16.5 versus 6.4 months (HR = 0.53; 95% CI 
0.31–0.9; P = 0.019). This suggests that diastolic 
hypertension correlates with drug efficacy [45]. 
Importantly, treatment of hypertension itself 
is not expected to affect antitumor activity [15]; 
thus, axitinib-induced hypertension should 
be aggressively managed with standard 
antihypertensives. Additionally, preliminary 
subset analysis of the phase 2 front-line study of 
axitinib with dose escalation has suggested that 
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pressure at , day 15 of cycle 1 compared with 
baseline (ΔdBP) ≥15 mmHg have a higher ORR 
than ΔdBP <15 mmHg (61% vs. 53%) [37].
CONCLUSION
In conclusion, axitinib has expanded available 
options for mRCC patients. Selective inhibition 
of the VEGFR-1, 2, and 3 at clinically applicable 
concentrations and biochemical potency 
against VEGFR contribute to its clinical efficacy. 
Prolonged median PFS is achievable compared 
with an active comparator in refractory patients, 
and is currently being evaluated in the front-line 
setting in mRCC. Analysis of patient-reported 
outcomes also suggests a delay in symptoms 
in patients with advanced RCC. Overall, the 
major dose-limiting adverse effects of axitinib 
include hypertension, diarrhea, and fatigue. 
Importantly, hypertension may be a useful 
biomarker of drug efficacy. Dose escalation is of 
considerable interest and is undergoing further 
evaluation in phase 2 studies. Ongoing phase 3 
studies are also assessing the role of axitinib in 
the front-line setting [46], as well as adjuvant 
treatment in high-risk patients [47]. 
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